Announcements Trials
Browse Landscape

Phase

Phase NA 2Phase 2 2Phase 4 1

Status

Completed 3Recruiting 2

Sponsor Class

OTHER 3INDUSTRY 2

Study Type

Interventional 5Observational 2

Sponsor

Cancer Type

Lymphoid 2CNS 2Plasma cell 1

Conditions

Breast Neoplasms 10184Neoplasms 7810Carcinoma, Non-Small-Cell Lung 5760Prostatic Neoplasms 5024Colorectal Neoplasms 4606Lung Neoplasms 3725Leukemia, Myeloid, Acute 3102Neoplasm Metastasis 3083Multiple Myeloma 3082Pancreatic Neoplasms 2845Melanoma 2653Ovarian Neoplasms 2573Lymphoma 2571Carcinoma, Hepatocellular 2480Stomach Neoplasms 2330Recurrence 2230Head and Neck Neoplasms 2103Precursor Cell Lymphoblastic Leukemia-Lymphoma 2086Lymphoma, Non-Hodgkin 2058Leukemia 2013Brain Neoplasms 1905Glioblastoma 1797Colonic Neoplasms 1791Leukemia, Lymphocytic, Chronic, B-Cell 1771Rectal Neoplasms 1720Uterine Cervical Neoplasms 1693Squamous Cell Carcinoma of Head and Neck 1654Lymphoma, Follicular 1652Lymphoma, Large B-Cell, Diffuse 1597Carcinoma, Renal Cell 1577

Interventions

Sodium Chloride 1Saline Solution 1Mn-PyC3A 1Dexmedetomidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Interventional × Neuroinflammatory Diseases × Clear all
NCT06745583 2026-06-03

A Phase 2 Study to Assess the Safety of EI-1071 and the Effects of EI-1071 on Neuroinflammation in Alzheimer's Disease Patients

Elixiron Immunotherapeutics (Hong Kong) Ltd.

Phase 2 Recruiting
15 enrolled
Lymphoid

Neuroinflammatory Diseases, Alzheimer Disease, Lymphoma, Follicular, Neurodegenerative Diseases, Cognitive Dysfunction

NCT07614243 2026-05-29

ZFAS1-BIPN

The First Affiliated Hospital of Zhejiang Chinese Medical University

Phase NA Completed
22 enrolled
Plasma cell

Neuroinflammatory Diseases, Multiple Myeloma

NCT04266665 2026-03-25

Effect of Dexmedetomidine on Brain Homeostasis and Neurocognitive Outcome

Aristotle University Of Thessaloniki

Phase 4 Completed
56 enrolled
CNS

Neuroinflammatory Diseases, Hypoxia, Brain Neoplasms

NCT06322342 2025-12-26

Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent

Reveal Pharmaceuticals Inc.

Phase 2 Completed
18 enrolled
CNS

Neuroinflammatory Diseases, Brain Neoplasms, Glioma, Meningioma, Multiple Sclerosis, Neoplasms, Neurilemmoma, Neurofibroma, Neuroma, Acoustic, Central Nervous System Neoplasms

NCT06112639 2025-01-10

DANCEREX-DTx

Fondazione Don Carlo Gnocchi Onlus

Phase NA Recruiting
192 enrolled
Lymphoid

Neuroinflammatory Diseases, Cognition Disorders, Dementia, Lymphoma, Follicular, Multiple Sclerosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡